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Abstract
This study describes the demographics and treatment status of HIV-infected adults accessing ambulatory care in the
Republic of Ireland and estimates diagnosed HIV prevalence rates. 3254 HIV-infected adults attended 1 of the 6
specialist HIV centres in the 12-month period 1st July 2009 to 30th June 2010. 2023/3254 (62%) were male, 1761/3133
(56%) Irish and 1048/3133 (34%) African. 1924/3098 (62%) resided in the Dublin area. The mean age was 39.8 years (SD
9.3); probable route of acquisition was available for 2898/3254 (89%); heterosexual acquisition accounted for 1442
(50%), MSM 777 (27%) and IDU 598 (21%). 2574/3202 (80%) were on highly active antiretroviral therapy (HAART).Of these
87% had HIV-RNA levels < 50cpm and 94% < 500cpm. The HIV diagnosed prevalence rate is estimated at 1.09/1000 nationally
and at 2.25/1000 in the Dublin area for 15-59 year olds
Introduction
Highly active antiretroviral treatment (HAART) has reduced the morbidity and mortality associated with Human
Immunodeficiency Virus (HIV) infection; it can also prevent onward transmission when HIV RNA level is suppressed.1,2 At
an individual level disease management aims to diagnose infection at an early stage and engage patients in specialist
care. At a societal level the focus is to provide timely disease surveillance and prevent onward transmission by an
expanded HIV test and treat approach.3 In Ireland, the Health Protection Surveillance Centre (HPSC) collates
demographic data on newly diagnosed HIV infections and reported 344 new diagnoses during 2013 bringing the cumulative
number reported as newly diagnosed to 6979 since the early 1980s.4 This information is valuable, however the
demographics and clinical status of patients living with HIV infection in Ireland have not been previously described.
This contrasts with the United Kingdom (UK), where Public Health England carries out an annual Survey of the Prevalence
of HIV-Infections Diagnosed (SOPHID).5 SOPHID, soon to be replaced by the HIV and AIDS reporting system (HARS), informs
each primary care trust of their diagnosed HIV prevalence rates and reports regular demographic data. Such data and
prevalence rates in Ireland were previously unknown. In 2008, in an effort to reduce the number of late presentations
the UK HIV testing guidelines were published; HIV diagnosed prevalence rates informed the cut-off at which routine
testing for HIV in healthcare settings was recommended.6 In areas of high diagnosed HIV prevalence (> than 2/1000 of
population aged 15-59) it is assumed that there is a corresponding high undiagnosed prevalence rate; audit data from
the United Kingdom have reported it as high as 28%.7 In these circumstances US data has shown the introduction of opt
out screening in healthcare settings is cost effective.8 This study was undertaken to describe the demographics and
treatment status of HIV infected adults accessing ambulatory care in the Republic of Ireland and to estimate the
diagnosed prevalence of HIV.
Methods
There are six sites for specialist adult (17 or over) HIV care in Ireland, three in Dublin: St James’s Hospital, Mater
Misericordiae University Hospital and Beaumont Hospital and three outside: Cork University Hospital, Galway University
Hospital and Limerick Regional Hospital. All newly diagnosed patients are referred to one of these centres for care.
The primary objective was to retrospectively identify the number of patients accessing specialist ambulatory care for
HIV-infection in Ireland (PACHI) over a 12-month period from July 2009 to June 2010. Secondary objectives included: to
record demographics; to record the attendances of each patient over the 12-month period; to collect antiretroviral
treatment (ART) data; to evaluate virological suppression in those on ART and using Irish 2011 population census data
estimate diagnosed prevalence rates for people living with HIV in Ireland as a whole and by region. Ethical approval
was sought at each individual centre. Data were pseudonymised and collated on an encrypted laptop provided by the HPSC.
Pseudonymisation created a unique code for each individual using initials and date of birth to allow comparison across
sites and prevent potential duplication. Consent was not obtained from individual patients as all information gathered
was from existing data sources and no individual patient identifiers were retained. Cases were retrospectively
identified using existing primary clinic datasets. Patients who attended at least one HIV specialist outpatient
appointment (physician-led) at one of the 6 centres from 1st July 2009 to 30th June 2010 met the inclusion criteria.
One investigator carried out all the data collection to maintain the reliability of the process. Demographics (gender,
age, county of residence, country of birth, probable route of acquisition) and the number of outpatient attendances in
the 12-month period were retrospectively manually extracted from primary clinic datasets, the hospital administration
systems or electronic patient records wherever the data was available. Most recent CD4 count and HIV RNA level were
extracted from primary datasets or computerized laboratory systems depending on the centre. Pharmacy data were
extracted from either paper records or pharmacy datasets depending on the site. An encrypted database was created for
each site; the data collection process had to be customised at each site due to the differing Information Technology
systems in existence across the 6 different hospital sites. A data dictionary was used from the initiation of the
study.
On completion of the study the 6 databases were merged into SPSS for analysis. HIV diagnosed prevalence rates for
Ireland and each county were estimated using 2011 population census data9 as a denominator. Data were primarily
descriptive. Independent samples T test was used to compare mean ages of males and females. Further analysis was
performed looking at numbers on antiretroviral treatment and viral suppression rates defined as HIV RNA level < 50 cpm.
For categorical variables: gender, country of origin and probable route of acquisition chi square analysis was
performed and for parametric variables: mean age and mean recent CD4 cell count analysis was performed using
independent samples t test. The number of outpatient visits were analysed using the Mann Whitney U test.
Results
Demographics
Over the 12-month period 3254 patients were identified as accessing specialist ambulatory care for HIV infection in
Ireland. 2642 (81.1%) accessed care in Dublin: St Jamesâs Hospital 1745 (53.6%), Mater Misericordiae University
Hospital 538 (16.5%), Beaumont Hospital 359 (11.0%), whilst 612 (18.8%) accessed care outside: Cork University Hospital
365 (11.2%), University College Hospital Galway 170 (5.2%) and Limerick Regional Hospital 77 (2.4%). 2023 (62.2%) were
male. Country of origin was available for 3133 (96.3%): 1761 (56.2%) were Irish; 1048 (33.5%) African; 133 (4.3%) from
Eastern Europe; 107 (3.4%) from Western Europe; 36 (1.2%) from Asia and 48 (1.5%) from another region. Probable route
of acquisition was available for 2898 (89.1%):heterosexual acquisition accounted for 1442 cases (49.8%); men having sex
with men (MSM) 777 cases (26.8%) and injecting drug users (IDU) 598 cases (20.6%).(Figure 1).
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Age
Overall the mean age was 39.8 (standard deviation, SD 9.3): the mean age for males was 41.5 (SD 9.7), which was
significantly older than the mean age for females of 37 (SD 8.1). (P value < 0.001, 95% confidence interval (CI)
3.8-5.1.)
Prevalence
Using 2011 population census data for ages 17-78 (age range of this cohort) and ages15-59 (age range reported
internationally) as denominators, HIV diagnosed prevalence rates are estimated by county. In the Republic of Ireland
the overall HIV diagnosed prevalence rate is estimated at 0.97/1000 and 1.09/1000 for ages 17-78 and 15-59
respectively. County of residence data were collected on 3098 cases and in the Dublin area the HIV diagnosed prevalence
rate is estimated at 2.0/1000 and 2.25/1000 for ages 17-78 and 15-59 respectively (Table 1).
Outpatient Department (OPD) Attendances
The median number of OPD attendances per patient in the twelve-month study period was 4 (Interquartile range IQR 2).
569/3251 patients (17.5%) attended OPD 6 or more times in the twelve-month period. 94/777 (12.1%) of MSMs,
81/538(15.1%) of male heterosexuals, 147/598 (24.6%) of IDUs and 187/904 (20.7%) female heterosexuals attended 6 or
more times.
Antiretroviral Treatment (ART)
Accurate ART data was available on 3202 (98.4%) patients. 2574/3202 (80.4%) were on ART. Those on ART were older; 40.7
v 36.2 years p < 0.001, and their median number of OPD visits was higher; 4.0 v 3.0 p < 0.001 (Table 2).
Viral Load Responses
HIV RNA values were available on 2528/2574 (98.2%) of patients on ART; 2208/2528 (87.3%) had HIV viral load responses
of < 50 copies per ml (cpm) and 2384/2528 (94.3%) < 500cpm. Those who were virally suppressed (defined as VL<50cpm)
were older; 41.1 v 37.8 years, p < 0.001 and had a higher CD4 count 541 cells/mm3 v 421 cells/mm3, P<0.0001 (Table 3).
For viral loads < 50cpm multi-variate analysis showed that only age remained significant with an odds ratio of 0.94(95%
CI 0.93-0.95).
Antiretroviral Regimens
ART regimen was recorded for 2488/2574 (96.7%) of patients on treatment. 1065 (42.3%) and 1073 (42.9%) were on a
nucleoside/nucleotide reverse transcriptase inhibitor backbone (NRTI) with a non-nucleoside reverse transcriptase
inhibitor (NNRTI) or protease inhibitor (PI) regimen respectively.
Discussion
We present, for the first time, a descriptive profile of HIV-infected patients accessing care in the Republic of
Ireland. These data describe a cohort of patients who are successfully accessing antiretroviral therapy. 80.4% of
patients attending clinics are on ART and of these 87.3% have reported HIV RNA levels of < 50 cpm. However caution is
needed as these data also highlight risk groups where barriers to treatment and compliance with treatment, reflected by
viral load suppression, when started is an on- going issue; notably in younger patients and injecting drug users.
Overall these data support the current model of specialist led regional HIV clinics in Ireland with additional
resources being required for higher needs patients. 3254 patients were identified as accessing care showing a
discrepancy with the number of new diagnoses ever reported to the HPSC since reporting began (6979). Notwithstanding
the limitations of this study along with natural attrition due to reported deaths of 50510 and emigrations, there
remain a large proportion of patients unaccounted for. This potentially highlights a group that may have been lost to
follow up and are no longer linked to specialist care. This is also reported as a concern in other cohorts
internationally, who report that 25%â44% of HIV-infected individuals are entirely lost to follow-up in many
settings.11, 12 This study was a retrospective, cross sectional study relying on outpatient clinic databases and patient
attendances to identify adults living with HIV. Patients who did not receive outpatient care, because they are not
engaged in care or who only accessed inpatient care, were not included. There is a small possibility of duplicate data,
however the author reviewed the final database to identify and remove same using the unique identifier of initials and
date of birth for each individual. Further limitations include: the collection of potentially incomplete data due to
the utilisation of multiple source documents; recall bias due the retrospective nature of the study and that the year
of diagnosis and thus duration of diagnosis was not collected. Lastly the absence of mortality data during the 12-month
period mean it is difficult to ascertain outcome data, despite the high ART use.
The data presented here are as a result of a valuable collaborative process between all 6 specialist HIV centres in
Ireland and the HPSC. It is the first study of its kind in Ireland to estimate prevalence of HIV and despite its
limitations will serve as a platform to initiate regular collation of these data. A crude national HIV diagnosed
prevalence rate amongst 15-59 year olds is estimated at 1.09/1000 and in the Dublin area this rate reaches 2.25/1000.
This study shows that Dublin is an area of high, diagnosed HIV prevalence and routine opt out testing for HIV in
healthcare settings should be considered with the aim of improving timely diagnosis where HIV status is unknown.
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